Similar articles for PMID: 24582485

Year	Number of Results
1975	1
1984	1
1985	3
1986	1
1987	2
1988	1
1990	1
1991	3
1992	2
1994	2
1995	3
1996	8
1998	1
1999	5
2000	4
2001	1
2002	6
2004	1
2005	2
2006	3
2007	2
2008	3
2010	2
2011	1
2012	1
2014	6
2015	7
2016	2
2024	0

1

Quality of life as a primary endpoint in ovarian cancer trials.

Mahner S, Burges A. Mahner S, et al. Lancet Oncol. 2014 Apr;15(4):363-4. doi: 10.1016/S1470-2045(14)70084-1. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582485 No abstract available.

2

Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.

Markman M. Markman M. Gynecol Oncol. 2008 Sep;110(3):275-7. doi: 10.1016/j.ygyno.2008.05.014. Epub 2008 Jun 30. Gynecol Oncol. 2008. PMID: 18586312 No abstract available.

3

Serious ethical dilemma of single-agent pegylated liposomal Doxorubicin employed as a control arm in ovarian cancer chemotherapy trials.

Markman M. Markman M. J Clin Oncol. 2010 Jul 1;28(19):e319-20; author reply e321-2. doi: 10.1200/JCO.2010.28.9934. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516447 No abstract available.

4

Primary chemotherapy versus primary surgery for ovarian cancer.

Scaletta G, Plotti F, Aloisi A, Angioli R. Scaletta G, et al. Lancet. 2015 Nov 28;386(10009):2142. doi: 10.1016/S0140-6736(15)01050-8. Lancet. 2015. PMID: 26638962 No abstract available.

5

Primary chemotherapy versus primary surgery for ovarian cancer.

Gasparri ML, Panici PB, Papadia A. Gasparri ML, et al. Lancet. 2015 Nov 28;386(10009):2142-3. doi: 10.1016/S0140-6736(15)01051-X. Lancet. 2015. PMID: 26638961 No abstract available.

6

Clinical trials of treatment of ovarian cancer.

Klaassen DJ, Boyes DA, Gerulath A, Levitt M, Pearson JG, Dodds D, Miller AB. Klaassen DJ, et al. Can Med Assoc J. 1975 Oct 18;113(8):717. Can Med Assoc J. 1975. PMID: 803183 Free PMC article. Clinical Trial. No abstract available.

7

Neoadjuvant chemotherapy for ovarian cancer: clarifying the confusion.

Wallach RC. Wallach RC. Oncology (Williston Park). 2008 Nov 30;22(13):1456; author reply 1456-7. Oncology (Williston Park). 2008. PMID: 19133602 No abstract available.

8

Chemotherapy for ovarian cancer.

Cvitkovic E, Misset JL. Cvitkovic E, et al. N Engl J Med. 1996 May 9;334(19):1269; author reply 1270. N Engl J Med. 1996. PMID: 8606730 No abstract available.

9

ICON3 and chemotherapy for ovarian cancer.

Ozols RF, Markman M, Thigpen JT. Ozols RF, et al. Lancet. 2002 Dec 21-28;360(9350):2086-7; author reply 2088. doi: 10.1016/S0140-6736(02)11984-2. Lancet. 2002. PMID: 12504453 No abstract available.

10

First-line chemotherapy for ovarian cancer - the controversy continues.

Kaye SB. Kaye SB. Br J Cancer. 2002 Oct 7;87(8):813-4. doi: 10.1038/sj.bjc.6600568. Br J Cancer. 2002. PMID: 12373592 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

74 results

Results by year